Voya Investment Management LLC Grows Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

Voya Investment Management LLC raised its position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 32.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 62,415 shares of the biopharmaceutical company’s stock after buying an additional 15,250 shares during the period. Voya Investment Management LLC owned approximately 0.08% of Xenon Pharmaceuticals worth $2,447,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the business. Blue Trust Inc. boosted its holdings in Xenon Pharmaceuticals by 140.3% in the fourth quarter. Blue Trust Inc. now owns 2,422 shares of the biopharmaceutical company’s stock valued at $95,000 after purchasing an additional 1,414 shares during the last quarter. Avior Wealth Management LLC purchased a new position in shares of Xenon Pharmaceuticals during the 4th quarter valued at approximately $101,000. KBC Group NV grew its position in shares of Xenon Pharmaceuticals by 39.8% during the fourth quarter. KBC Group NV now owns 2,742 shares of the biopharmaceutical company’s stock worth $107,000 after buying an additional 780 shares in the last quarter. Magnetar Financial LLC bought a new stake in shares of Xenon Pharmaceuticals in the fourth quarter worth $210,000. Finally, HighMark Wealth Management LLC raised its holdings in Xenon Pharmaceuticals by 22.0% in the fourth quarter. HighMark Wealth Management LLC now owns 6,100 shares of the biopharmaceutical company’s stock valued at $239,000 after acquiring an additional 1,100 shares in the last quarter. 95.45% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the stock. William Blair reissued an “outperform” rating on shares of Xenon Pharmaceuticals in a research report on Friday, February 28th. Deutsche Bank Aktiengesellschaft started coverage on Xenon Pharmaceuticals in a research note on Tuesday, February 11th. They set a “buy” rating and a $67.00 price objective on the stock. Royal Bank of Canada reiterated an “outperform” rating on shares of Xenon Pharmaceuticals in a research report on Friday, February 28th. StockNews.com cut Xenon Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday. Finally, The Goldman Sachs Group dropped their target price on shares of Xenon Pharmaceuticals from $60.00 to $52.00 and set a “buy” rating on the stock in a report on Thursday, April 17th. One investment analyst has rated the stock with a sell rating and ten have issued a buy rating to the company’s stock. According to MarketBeat, Xenon Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $56.78.

Xenon Pharmaceuticals Trading Up 0.5 %

Shares of NASDAQ XENE opened at $38.28 on Friday. Xenon Pharmaceuticals Inc. has a 12-month low of $26.74 and a 12-month high of $46.00. The company has a market cap of $2.93 billion, a PE ratio of -13.57 and a beta of 1.21. The stock has a 50 day simple moving average of $34.74 and a 200-day simple moving average of $38.57.

Xenon Pharmaceuticals (NASDAQ:XENE) last released its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.84) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.89) by $0.05. Sell-side analysts forecast that Xenon Pharmaceuticals Inc. will post -3.1 earnings per share for the current fiscal year.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.